Otsuka Pharmaceutical

Medicines and Research from Japan

Otsuka Pharmaceutical is a Japanese company with a global presence, focused on developing medicines and nutraceutical products. Its Spanish subsidiary, Otsuka Pharmaceutical S.A., is the company’s longest-established subsidiary in Europe and operates under the coordination of Otsuka Pharmaceutical Europe Ltd. (OPEL), based in the United Kingdom.

Research and Approach

The company researches and develops treatments for common and rare diseases. It reported investing €1.9 billion in research and development in 2024 and has a network of 32 research institutes worldwide. Otsuka says its purpose is to improve patients’ health, putting the needs of patients, caregivers, and health care professionals at the center of its work.

Products

Product information is intended exclusively for health care professionals residing in Spain who are authorized to prescribe or dispense medicines. All products require a prescription. The portfolio includes:

• ABILIFY (aripiprazole): tablets, orally disintegrating tablets, oral solution, and injectable solution.
• ABILIFY MAINTENA (aripiprazole): extended-release injectable suspension in vials and prefilled syringes, at 720 mg and 960 mg doses every two months.
• RXULTI (brexpiprazole): film-coated tablets.
• DELTYBA (delamanid): film-coated tablets.
• LUPKYNIS (voclosporin): soft capsules.
• JINARC (tolvaptan): tablets in several strengths.
• SAMSCA (tolvaptan): tablets.
• INAQOVI (decitabine and cedazuridine): film-coated tablets.

Transparency and Ethics

Otsuka publishes information about transfers of value to health care professionals, health care organizations, and patient organizations, in accordance with current regulations. It has a Group Code of Ethics for business partners and a Speak Up ethics channel for reporting potential misconduct.

Clinical Research

Otsuka says it is committed to publicly sharing information about its clinical trials through its website.